The clinical benefit of adoptive transfer of MHC-restricted cytotoxic T lymphocytes(CTL) 
Introduction
T cells are equipped with unique antigen recognition units, the T cell receptors (TCR) that are composed of polymorphic TCR αβ 1 or γδ 2 chains and the non-polymorphic CD3-γ, δ, ε and ζ signaling molecules. 3, 4 The CD8 + cytotoxic T lymphocytes (CTL) play an essential role in the eradication of virally infected cells and tumor cells, and specifically recognize and kill cells that present antigenic peptides in the context of MHC class I molecules. 5, 6 Isolation and expansion of such CTL has allowed for the identification of genes that code for tumor rejection antigens (TRA), such as the melanoma-associated MAGE genes. 7, 8 Peptides presented by MHC class I molecules are usually between eight and 10 amino acids long and are buried in a peptide binding groove, which consists of two antiparallel α-helices overlaying a platform of antiparallel β-strands. 9 Two or three positions in the peptide, the anchoring residues, fit into hydrophobic pockets formed by the variable residues in the peptide binding groove. 10, 11 Exposed peptide residues and non-buried elements of the two α-helices are critical for the recognition of the peptide/MHCcomplex by TCR. 12 MHC-restricted CTL with specificities for a wide range of TRA, such as tyrosinase, MART-1, gp100, p15, TRP-1, β-catenin, MAGE, BAGE and GAGE, have been identified and isolated from cancer patients or have been generated in vitro. 13 The identification of these peptides has trig-gered the development of new immune treatment strategies, aimed either at the induction of specific T cell responses by vaccination, 14, 15 or the adoptive transfer of in vitro generated MHC-restricted CTL. 6 TRA-specific T lymphocytes, however, occur only at low frequencies in a small proportion of patients, probably because many of these TRAs represent normal differentiation antigens and are of a tolerogenic nature. This low CTL frequency together with the difficulties associated with in vitro generation of CTL-specific for cancers other than melanoma makes CTL-based immunotherapy impractical. In addition, it is important to note that peptide specific CTL generated in vitro by incubation of PBMC with peptide pulsed APC were reported to respond to peptide-pulsed target cells, but not to native antigen presenting tumor cells. 16 Moreover, CTL generated in vivo by vaccination with peptide-loaded antigen presenting cells (APC) do not necessarily respond to native tumor antigenpresenting tumor cells. 17, 18 Gene-based strategies were developed which aimed at transferring specificities to primary human T lymphocytes via chimeric Ig or TCR molecules. 19, 20 Chimeric Igbased receptors with specificities for tumor-associated, MHC non-restricted antigens (TAA) can be functionally expressed on human T lymphocytes. [21] [22] [23] [24] These genetically introduced chimeric receptors do not affect the requirement of co-activation and adhesion receptors to activate T lymphocytes. 25 However, in contrast to TAA, TRA are processed intracellularly and presented as peptides in MHC molecules, and hence are not recognized by 'classical' mAbs per se. In addition, we recently showed that chimeric TCR αβ receptors can confer human T lymphocytes with MAGE-A1/HLA-A1 speci-ficity. 26 However, the applicability of T cell grafting with antitumor specificity is still limited by the availability of peptide/MHC-specific T cell clones. Methods that allow for in vitro selection of TRA-specific molecules from large repertoires would potentially provide a pool of tumorreactive molecules. Thus far, several approaches have been explored to obtain molecules that bind MHC-restricted antigens on tumor cells. First, TCR libraries specific for peptide/MHC complexes were generated, 27-29 but engineering of TCR proved difficult and the TCR were of low binding affinity. 30, 31 Second, monoclonal antibodies (mAbs), with MHC-restricted specificity were generated by immunizing mice with soluble peptide-MHC complexes or antigen-presenting cells. Unfortunately, these immunization protocols were rarely successful. [32] [33] [34] [35] In this paper, we exploited the selection power of phage display that allows for the testing of tens of millions of individual clones with a high-throughput selection of Fabs with peptide/MHC complex binding capacity. Following this strategy, we recently selected a fully human Fab fragment, termed Fab-G8, specific for HLA-A1/MAGE-A1 complexes from a large non-immune phage-antibody repertoire. 36 The isolated phage specifically binds to MAGE-A1 peptide pulsed HLA-A1 POS B-LCL, as well as to MAGE-A1 peptide presented by HLA-A1 molecules on antigen-expressing tumor cells.
Here we report on the construction and retroviral transfer of a chimeric receptor based on this phage display selected Fab fragment, and its use to genetically program primary human T lymphocytes with an immune specificity. The Fab-G8 gene fragment was ligated via the CD4 transmembrane domain to the intracellular Fc(ε)RIγ chain signaling molecule, resulting in the Fab-G8-CD4/γ receptor, which was retrovirally introduced into human T lymphocytes. Fab-G8-CD4/γ POS T lymphocytes specifically bound MAGE-A1/HLA-A1 complexes. Human T lymphocytes expressing this MHC restricted Fab-based chimeric receptor on their membrane specifically responded to both MAGE-A1 peptide pulsed HLA-A1 POS B cell blasts and native MAGE-A1 POS /HLA-A1 POS melanoma cells by specific tumor cell lysis, as well as cytokine production. Thus, peptide/MHC-specific chimeric Fab fragments can be used to retarget human T lymphocytes to TRA epitopes, which may provide a novel rationale for developing clinical immune-gene therapeutic modalities independent of CTL-derived TCR.
Results

Retroviral transduction of human T lymphocytes with the Fab-G8-CD4/γ receptor
The heavy and lambda light chains from the human Fab fragment G-8 specific for MAGE-A1/HLA-A1 were obtained from a non-immune human Fab library. 36 Amplification by PCR introduced SfiI and NotI restriction sites, which enabled insertion into a retroviral expression cassette. The retroviral expression cassette used, comprises a signal sequence derived from the G250 monoclonal antibody (mAb) heavy chain, cloning sites, a short Ig constant kappa spacer (C) linked to the CD4 transmembrane domain and the intracellular domain of the Fc(ε)RIγ chain. Inclusion of the CD4 transmembrane domain and the intracellular domain of the Fc(ε)RIγ chain in chimeric mAb-based receptor constructs resulted in increased membrane expression. 23 The cassette was inserted into the retroviral vector pBullet. 26 The amplified heavy and lambda chain fragments were cloned individually into this retroviral expression cassette resulting in Fab-G8-CD4/γ heavy and light chain retroviral vectors ( Figure 1 ). The Fab-G8-CD4/γ retroviral vectors were then introduced into CD4-depleted, OKT3 mAb-activated primary human T lymphocytes by cocultivation with 293T cells, that had been transfected with both the heavy and lambda retroviral vectors and retroviral packaging constructs. 23 As a control, activated human T lymphocytes were cocultivated with 293T packaging cells that were transfected with an empty pBullet vector.
Fab-G8-CD4/γ POS human T lymphocytes specifically bind MAGE-A1/HLA-A1 complexes
Membrane expression of Fab-G8-CD4/γ receptors on transduced human T lymphocytes was analyzed by incubating the cells with soluble MAGE-A1/HLA-A1/streptavidin PE complexes, that had also been used to isolate the original Fab G-8 phage. As shown in Figure  2a , about 3% of the transduced human T lymphocytes specifically bound soluble MAGE-A1/HLA-A1 complexes. MAGE-A1/HLA-A1/streptavidin PE complex binding T lymphocytes were enriched using anti-PE mAb coated magnetic beads as described in Materials and methods. This resulted in more than 90% Fab-G8-CD4/γ receptor POS T lymphocytes ( Figure 2b ). Enriched Fab-G8-CD4/γ POS T lymphocytes were in vitro expanded and used in all subsequent experiments. Nonspecific binding was not observed, neither for mock-transduced T lymphocytes using soluble MAGE-A1/HLA-A1 complexes (Figure 2d ), nor for Fab-G8-CD4/γ receptor POS human T lymphocytes using soluble influenza/HLA-A1/streptavidin PE complexes (Flu/HLA-A1). The CTL clone MZ2-82/30 expressing an MAGE-A1/HLA-A1-specific TCR was used as a positive control (Figure 2c ). FACS analysis of the Fab-G8-CD4/γ transduced T lymphocytes (ie CD4, CD8,CD56, CD16 and TCR γδ) showed that the effector populations almost exclusively consist of CD8 POS cells (data not shown).
Fab-G8-CD4/γ POS primary human T lymphocytes specifically produce IFN-γ upon stimulation with immobilized MAGE-A1/HLA-A1 complexes
We also determined whether Fab-G8-CD4/γ POS primary human T lymphocytes could be activated by immobilized MAGE-A1/HLA-A1 complexes to produce IFN-γ. To this end, we incubated transduced human T lymphocytes for 18-20 h either on immobilized MAGE-A1/HLA-A1 com- 
Figure 2 Cell surface expression of the Fab-G8-CD4/γ receptor on transduced primary human T lymphocytes. Cell surface expression of the Fab-G8-CD4/γ receptor was analyzed by incubation of T lymphocytes with relevant MAGE-A1/HLA-A1/streptavidin PE complexes (M1/A1, bold line) and irrelevant influenza/HLA-A1/streptavidin PE complexes (Flu/A1, normal line). The following cell samples were used: primary human T lymphocytes transduced with Fab-G8-CD4/γ retroviral vectors (a); human T lymphocytes transduced with Fab-G8-CD4/γ retroviral vectors, followed by selection with MAGE-A1/HLA-A1/streptavidin PE complexes and anti-PE mAb-coated magnetic beads (b); the HLA-A1 restricted, MAGE-A1 specific parental CTL clone MZ2-82/30 (positive control) and mock-transduced human T lymphocytes (negative control) (c and d, respectively).
plexes or control Flu/HLA-A1 complexes and analyzed cells by IFN-γ capture assay (see Materials and methods). Only MAGE-A1/HLA-A1 complexes, but not control Flu/HLA-A1 complexes, triggered Fab-G8-CD4/γ POS primary human T lymphocytes to produce IFN-γ ( Figure 3) . Moreover, no IFN-γ was produced when mocktransduced T lymphocytes were incubated with peptide/MHC complexes. A clear IFN-γ production was observed when CTL clone MZ2-82/30 was stimulated with MAGE-A1/HLA-A1 complexes, but not control complexes.
Fab-G8-CD4/γ POS primary human T lymphocytes specifically respond to MAGE-A1 peptide pulsed HLA-A1 POS target cells by cytolysis and cytokine production
To analyze Fab-G8-CD4/γ POS primary human T lymphocytes for their responsiveness to cellular targets expressing MAGE-A1/HLA-A1, we incubated transduced T lymphocytes, in a first set of experiments, with HLA-A1 POS EBV-transformed B cell blasts (B-LCL APD) which were externally loaded with MAGE-A1 peptide (at 10 g/ml final). B cell blasts were incubated with an irrelevant influenza virus peptide to monitor nonspecific responses. Only B-LCL pulsed with MAGE-A1 peptide, but not influenza virus peptide were able to trigger target cell lysis by Fab-G8-CD4/γ POS T lymphocytes ( Figure 4 ). In addition, triggering of TNF-α and IFN-γ production was observed when Fab-G8-CD4/γ POS T lymphocytes were incubated with MAGE-A1 peptide pulsed target cells, but not with irrelevant influenza peptide pulsed target cells ( Figure 5 ). Neither target cell lysis nor cytokine production was observed when mock transduced T lymGene Therapy
Figure 3 IFNγ production by Fab-G8-CD4/γ POS human T lymphocytes upon incubation with immobilized MAGE-A1/HLA-A1 complexes. IFNγ production by the Fab-G8-CD4/γ transduced T lymphocytes upon incubation with immobilized MAGE-A1/HLA-A1 complexes (shaded area) or control influenza peptide/HLA-A1 complexes (white area) was determined by flow cytometry as described in Materials and methods. Events shown represent viable lymphocytes stained with PE labeled anti-IFNγ mAb. The following cell samples were used: (a) Fab-G8-CD4/γ transduced T lymphocytes, (b) mock transduced T lymphocytes (negative control), and (c) CTL MZ2-82/30 (positive control).
phocytes were used as effector cells. As a positive control for specific cytolysis and cytokine production the CTL MZ2-82/30 was used. (Figure 6a) , and triggered specific production of TNF-α and IFN-γ (Figure 7 ). MHC restriction of the observed lysis was further illustrated by the significant inhibition of Fab-G8-CD4/γ POS T lymphocyte-mediated target cell lysis following addition of anti-class I mAbs (Figure 6b ). Negative controls comprised addition of irrelevant mAbs, or incubation of MAGE-A1 POS , HLA-A1 POS melanoma cells with mock transduced T lymphocytes. Moreover, the cytolytic responses of the Fab-G8-CD4/γ POS T lymphocytes are clearly inhibited by the addition of anti-CD8 mAb demonstrating that indeed the effector population almost exclusively consists of CD8 POS cells (data 
Figure 5 Fab-G8-CD4/γ POS human T lymphocytes produce TNFα and IFN-γ upon stimulation with MAGE-A1 peptide pulsed target cells. Fab-G8-CD4/γ POS human T lymphocytes (6 × 10
) were incubated for 2h with HLA-A1 POS EBV transformed B cell blasts (2 × 10
) in the presence of MAGE-A1 or influenza peptide (at 10 g/ml final). Production of TNF-α (a) and IFN-γ (b) was quantified by ELISA, as described in Materials and methods.
not shown). As a positive control again CTL MZ2-82/30 was used.
Discussion
In this study we show efficient retargeting of human T lymphocytes to tumor cells presenting the MAGE-A1 antigen in the context of the MHC class I molecule HLA-A1 by retroviral introduction of a human Ig-based chimeric receptor. The chimeric receptor was made by ligation of the anti-MAGE-A1/HLA-A1 Fab-G8 to the CD4 transmembrane domain and intracellular Fc(ε)RIγ chain, and was successfully transduced into primary human T lymphocytes. Human T lymphocytes expressing this MHC restricted Fab-G8-CD4/γ receptor specifically bound MAGE-A1/HLA-A1 complexes. Moreover, Fab-G-8-CD4/γ POS T lymphocytes specifically responded to both MAGE-A1 peptide pulsed HLA-A1 POS B cell blasts and native MAGE-A1 POS /HLA-A1 POS melanoma cells by specific tumor cell lysis, as well as cytokine production. The MHC restriction of the observed immune reactivities was demonstrated by a significant reduction of target cell lysis by anti-MHC class I mAbs.
Antibody-based retargeting of T cells has already been achieved to tumor-associated antigens (TAA). [21] [22] [23] [24] However, this is the first report on an Ig-based chimeric receptor conferring MHC-restricted tumor specificity to primary human T cells. Since most known TRAs are in fact MHC restricted peptides, this may have major implications for immunotherapy. Adoptive immunotherapy by clinical transfer of autologous tumor or virus-specific T cells and interleukin-2 has met success in the treatment of both hematological malignancies and melanoma, 6, 37 and viral diseases caused by CMV and EBV. 5 The overall difficulty in obtaining tumor-reactive TIL from individual patients, and TIL specific for cancers other than melanoma, however, has hampered the development of clinically effective adoptive immunotherapeutic strategies. Research focussed on the engineering of chimeric receptors to transfer specificities to T lymphocytes. Our laboratory developed strategies to genetically program human T lymphocytes with non-MHC restricted (Ab-based) and MHC-restricted (TCR-αβ-based) chimeric receptors. 19, 20 Chimeric single chain or double chain Ig or TCR receptor POS T lymphocytes specifically respond to tumor cells expressing the relevant antigen by tumor cell kill and cytokine production. 22, 26 However, in the case of TRA epitopes, this approach is still limited by the isolation of tumor-specific CTLs required for the cloning of TCR genes. A complete in vitro approach would allow for the selection of TRA-specific molecules, without being limited by the availability of CTL clones. The ability to produce numerous HLA complexes in vitro, 38 as well as the availability of large non-immune human phage-antibody libraries has made such an in vitro approach within reach. 36 In principle, any peptide with the right anchoring residues may be refolded in vitro with MHC class I heavy chain and β2 microglobulin, resulting in peptide/MHC complexes available for phage selection. Indeed, we have recently used our non-immunized library to select human antibodies against 12 HLA-A2 complexes presenting different peptides and we were able to isolate between three and nine different antibodies for each complex, some of them of high affinity, in less than 4 weeks (manuscript in preparation). This shows that it is possible to rapidly select anti-peptide/MHC antibodies against any complex and that this technology may become a reliable source of viral or TRA-specific receptors in the near future. In contrast to TCRs, Fab fragments can be easily produced in E. coli, making it possible to determine and modulate the fine specificity of Fab fragments by antibody-engineering techniques before their use in retargeting experiments. Hence, we believe that the use of phage display will prove to be a flexible tool to select and modulate TRAspecific Fab molecules.
susceptible to lysis by Fab-G8-CD4/γ transduced T lymphocytes. Cytotolytic activity of human T lymphocytes versus MAGE-A1 expressing melanoma cells was determined as described in legend to Figure 4. MAGE-A1 POS and HLA-A1 POS melanoma cells (ie MZ2-MEL 3.0) and MAGE-A1 NEG and/or HLA-A1 NEG cell lines of different histologies (ie MEL 2A, MEL 78 and SKRC17 cl4) were used as target cells. Target cells were incubated with (1) Fab-G8-CD4/γ transduced T lymphocytes (a and b); (2) mock transduced T lymphocytes (negative control, c and d); and (3) CTL MZ2-82/30 (positive control, e and f). Anti-HLA-ABC or mouse Ig (both at 10 g/ml final) was added to the melanoma target cells (ie MZ2-MEL 3.0) 15-30 min before incubation with the effector T lymphocytes (b, d and f). Mean percentages
Fab-G8 has an affinity with a K D of 250 nm, which is already high compared to TCR/peptide MHC interactions (average K D around 10 -5 to 10 -6 m). We have recently improved the affinity of Fab-G8 by a factor of 18. During this process, low affinity variants have also been generated. Different mutants of Fab-G8 with the same peptide fine-specificity, but covering a large range of affinities, with K D s varying from 1300 to 14 nm are thus available (manuscript in preparation). The effect of receptor affinity on T cell retargeting and killing is currently being investigated. Moreover, we suggest that this Fab-CD4γ
Gene Therapy fusion may be used for comparative functional analyses between antibody-based and TCR-based T cell retargeting. Preliminary results show that it is possible to retarget T cells using a double chain TCR directed against MAGE-A1/HLA-A1 fused to Fc(ε)RIγ. The TCR-based and Fab-G8-based constructs have identical specificities and signaling moieties, providing powerful tools for investigating the requirements of additional interactions upon peptide/MHC binding, such as TCR accessory molecules.
Human T lymphocytes positive for a single chain Fv receptor with the same CD4/γ domain show CD3 independence for their cytotoxic response, 25 implying that receptors with this type of configuration do not associate with endogenous CD3. The exact membrane topology of the Fab-based receptors is currently under investigation.
In conclusion, the efficiency and reproducibility of T cell retargeting with chimeric receptor genes combined with the flexibility of antibody phage display to select TRA specific molecules hold great promise for clinical immunogene therapy. 
Materials and methods
Cells and antibodies
Human T lymphocytes were derived from healthy donors, and were isolated and expanded as described. 22 Target cell lines used in this study were: (1) NEG renal carcinoma cell line SKRC17-cl4 (kindly provided by E Oosterwijk, Academic Hospital Nijmegen); and (6) the HLA-A1 POS EBV-transformed B cell blast APD. The human embryonic kidney cell line 293T 39 (kindly provided by Y Soneoka, University of Oxford, Oxford, UK) was used as a packaging cell line for the pBullet Fab-G8-CD4/γ retroviral vectors essentially as described. 23 The HLA-A1-restricted, MAGE-A1 specific CTL clone MZ2-82/30 (kindly provided by T Boon and P Coulie) was used as a positive control in these studies. The following mAbs were used this study: anti-CD4 mAb (Becton Dickinson Biosciences, San Jose, CA, USA), anti-class I mAb W6/32 (Seran Laboratories, Crawley Down, UK) and purified mouse Ig (Nordic, Tilburg, The Netherlands).
Construction of the chimeric Fab-G8-CD4/γ genes
The chimeric heavy chain VhChCD4/γ and lambda light chain VlClCD4/γ were generated by amplification of the Fab fragments from phage G8 DNA, 36 using the primer pairs Vh-SfiI/Ch-NotI and Vl-SfiI/Cl-NotI, respectively. The resulting fragments were inserted via SfiI/NotI digests into the pBullet retroviral vector, which contains an expression cassette. The expression cassette contains: (1) the G250 variable heavy chain signal sequence, and (2) a constant kappa chain linker (Ck), the CD4 transmembrane domain and the intracellular γ chain (CD4/γ). All domains were derived from the G250 specific chimeric scFv-HKCD4/γ receptor DNA. 23 Primer sequences were as follows: Vh-SfiI: 5'-CTC-TGG-CCC-AGC-CGG-CCA-TGG-CCG-AGG-TGC-AGC-TGG-TGG-AGT-CTG-GG-3'; Ch-NotI: 5'-CTC-TGC-GGC-CGC-GCT-TGA-GAC-GGT-GAC-CGT-GGT-CCC-3'; Vl-SfiI: 5'-CTC-TGG-CCC-AGC-CGG-CCA-TGG-CCC-AGT-CTG-TGC-TGA-CTC-AGC-CAC-CCT-CG -3', and Cl-NotI: 5'-CTC-TGC-GGC-CGC-GAG-GAG-GGT-CAG-CTT-GGT-CCC-TCC-3'.
Retroviral transduction of Fab-G8-CD4/γgenes into primary human T lymphocytes and in vitro expansion of transduced T lymphocytes CD4
POS T lymphocytes were depleted from human peripheral blood lymphocytes (PBL) with anti-CD4 mAb coated magnetic beads according to the manufacturer's instructions (Dynal, Oslo, Norway). The CD4-depleted human PBL (5 × 10 6 ) were activated by addition of anti-CD3 mAb and then transduced using the pBullet retroviral vectors with the Fab-G8-CD4/γ genes as described earlier. 23 Briefly, anti-CD3 mAb activated lymphocytes were incubated for 72 h with an irradiated (25 Gy) monolayer of recombinant retrovirus producing 293T cells using culture medium supplemented with 4 g/ml polybrene (Sigma, St Louis, MO, USA) and 360 IU/ml human rIL-2 (Proleukin; Chiron, Amsterdam, The Netherlands). Expansion of transduced primary human T lymphocytes was performed in the presence of feeder cells as described elsewhere. 40, 41 Flow-cytometric analysis of retrovirally transduced primary human T lymphocytes Primary human T lymphocytes (5 × 10 5 ) were stained with soluble peptide/HLA-A1/streptavidin PE complexes as described. 26 Briefly, T lymphocytes (5 × 10 5 ) were incubated for 30 min on ice, with a 1:10 dilution of freshly prepared complexes in a volume of 20 l. The dot plots show viable T lymphoblasts gated on forward (FSC) and sideward (SSC) light scatter signals. Analysis was performed on a FACSCAN instrument (Becton Dickinson Biosciences, San Jose, CA, USA). Human T lymphocytes were stained with soluble peptide/HLA-A1/ streptavidin PE complexes and enriched via anti-PE mAb coated magnetic beads and mini-MACS columns according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany).
IFNγ capture assay
Transduced human T lymphocytes were incubated for 18-20 h on immobilized peptide/MHC complexes and were analyzed by flow cytometry for IFN-γ production. To immobilize peptide/MHC complexes, non-tissue culture 24-well plates were incubated with PBS containing streptavidin (at 1 mg/ml final) for 12-15 h at room tem-perature (RT). Non-bound streptavidin was removed by three washes with PBS. The 24-well plates were then blocked with PBS containing 2% FCS and 2 mm EDTA for 30 min at RT. After removal of the blocking medium, soluble biotinylated MAGE-A1/HLA-A1 complexes and influenza/HLA-A1 complexes (at 10 g/ml final) were added to the streptavidin-coated plates, and left to bind for an additional 30 min at RT. To remove non-bound peptide/MHC complexes, the plates were washed twice with PBS and once with culture medium. Finally, transduced T lymphocytes (1 × 10 6 cells) were then stimulated in the peptide/MHC complex-coated plates for 18-20 h at 37 o C/5% CO 2 in a volume of 1 ml. IFNγ production was determined by IFNγ capture assay (Miltenyi Biotec) according to the manufacturer's protocol.
Cytotoxicity assays
Cytolytic activities of Fab-G8-CkCD4/γ transduced human T lymphocytes were measured in 6 h 51 Cr-release assays as described elsewhere. 22 The percentage-specific 51 Cr release was calculated as follows: ((test counts Ϫ spontaneous counts)/(maximum counts Ϫ spontaneous counts)) × 100%. Spontaneous
51
Cr release was always less than 10% of maximum release. Peptide loading of target cells was performed by addition of a MAGE-A1 nonapeptide (EADPTGHSY, Leiden University Medical Center, Leiden, The Netherlands) or an irrelevant influenza peptide derived from influenza virus A nucleoprotein (CTELKLSDY, Leiden University Medical Center) to the target cells 5-15 min before incubation with effector T lymphocytes. In blocking experiments, anti-class I mAbs were added to the target cells 15-30 min before addition of the T lymphocytes (W6/32 or irrelevant mIg, both at 10 g/ml final).
TNFα and IFN-γ ELISA
To quantify secreted amounts of TNFα and IFN-γ, transduced human T lymphocytes (6 × 10 4 ) were cultured for 24 h either in the presence or absence of 2 × 10 4 adherent tumor cells in culture medium supplemented with 360 IU/ml rIL-2. Supernatants were harvested and levels of TNFα and IFN-γ, were measured by standard ELISA according to the manufacturer's instructions (CLB, Amsterdam, The Netherlands).
